Growth Metrics

Integra Lifesciences Holdings (IART) Cash from Operations (2016 - 2026)

Integra Lifesciences Holdings' Cash from Operations history spans 17 years, with the latest figure at 11816000.0 for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 76.71% to 11816000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 50384000.0, a 61.06% decrease, with the full-year FY2025 number at 50384000.0, down 61.06% from a year prior.
  • Cash from Operations hit 11816000.0 in Q4 2025 for Integra Lifesciences Holdings, down from 40906000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for IART hit a ceiling of 91290000.0 in Q2 2021 and a floor of 11257000.0 in Q1 2025.
  • Historically, Cash from Operations has averaged 44830850.0 across 5 years, with a median of 42625000.0 in 2022.
  • Biggest five-year swings in Cash from Operations: surged 231.9% in 2021 and later plummeted 171.45% in 2025.
  • Tracing IART's Cash from Operations over 5 years: stood at 69277000.0 in 2021, then increased by 23.18% to 85334000.0 in 2022, then plummeted by 31.15% to 58750000.0 in 2023, then decreased by 13.63% to 50740000.0 in 2024, then plummeted by 76.71% to 11816000.0 in 2025.
  • Business Quant data shows Cash from Operations for IART at 11816000.0 in Q4 2025, 40906000.0 in Q3 2025, and 8919000.0 in Q2 2025.